Why Cara Therapeutics Stock Is Crashing Today
Shares of Cara Therapeutics (NASDAQ: CARA) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study evaluating oral Korsuva in treating moderate-to-severe pruritis in patients with atopic dermatitis.
With the biotech stock falling so heavily today, you'd think that all the results from the phase 2 trial were really bad. That wasn't entirely the case, though.
Image source: Getty Images.
Source Fool.com
